强化化疗7&3方案对比维奈克拉联合低甲基化剂治疗急性髓系白血病的真实世界疗效
研究基于全国电子健康记录数据库和宾夕法尼亚大学电子健康记录,纳入60-75岁无器官衰竭史的新诊断急性髓系白血病患者,比较7&3方案(312例)与维奈克拉联合低甲基化剂(ven/HMA,488例)的真实世界结局。强化化疗组中位总生存期22个月,ven/HMA组10个月(HR 0.53,95%CI 0.40-0.60);校正基线特征不平衡后生存优势减半(HR 0.71,95%CI 0.53-0.94);倾向性均衡亚组两组总生存期相似(HR 1.10,95%CI 0.75-1.6)。ven/HMA组60天死亡率更高(15% vs 6%),尽管7&3组记录感染和发热性中性粒细胞减少更多。
要点
- 强化化疗组中位总生存期22个月,ven/HMA组10个月(HR 0.53,95%CI 0.40-0.60)。
- 校正基线特征后生存优势减半(HR 0.71,95%CI 0.53-0.94)。
- 倾向性均衡亚组两组总生存期相似(HR 1.10,95%CI 0.75-1.6)。
核心结论
- 在多中心真实世界数据集中,选择强化化疗的患者总生存期更优,但很大一部分患者接受ven/HMA结局相似。
- 需要前瞻性随机研究控制可测量和不可测量的混杂因素来确认此结果。
研究设计与样本
- 回顾性分析全国电子健康记录衍生数据库和宾夕法尼亚大学电子健康记录中新诊断的急性髓系白血病患者。
- 纳入60-75岁无器官衰竭史患者,7&3组312例,ven/HMA组488例。
主要发现
- ven/HMA组患者年龄更大,更可能有继发性急性髓系白血病、不良细胞遗传学和不良突变。
- 强化化疗组中位总生存期22个月 vs ven/HMA组10个月(HR 0.53,95%CI 0.40-0.60)。
- 控制基线特征不平衡后生存优势减半(HR 0.71,95%CI 0.53-0.94)。
- 接受任一治疗可能性至少30%-70%的倾向性均衡亚组总生存期相似(HR 1.10,95%CI 0.75-1.6)。
- ven/HMA组60天死亡率更高(15% vs 6%),尽管7&3组记录感染和发热性中性粒细胞减少更多。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Intensive chemotherapy with cytarabine and anthracycline (7&3) remains the standard therapy for patients medically fit for induction, but the assessment of fitness remains controversial. Venetoclax and hypomethylating agent (ven/HMA) combination therapy has improved outcomes in unfit patients but no prospective study has assessed ven/HMA versus 7&3 as initial therapy in older, fit patients. Given no studies and expectation of ven/HMA use in patients outside of trial criteria, we evaluated retrospective outcomes among newly diagnosed patients. A nationwide electronic health record (EHR)-derived database and the University of Pennsylvania EHR identified 312 patients receiving 7&3 and 488 receiving ven/HMA who were 60-75 years old without history of organ failure. Ven/HMA patients were older and more likely to have secondary AML, adverse cytogenetics, and adverse mutations. Median overall survival (OS) for patients receiving intensive chemotherapy was 22 versus 10 months for ven/HMA (HR 0.53, 95% CI 0.40-0.60). Controlling for measured baseline characteristic imbalances reduced survival advantage by half (HR 0.71, 95% CI 0.53-0.94). A sub-group of patients with equipoise, likelihood at least 30%-70% of receiving either treatment, had similar OS outcomes (HR 1.10, 95% CI 0.75-1.6). Regarding safety outcomes, 60-day mortality was higher for ven/HMA (15% vs. 6% at 60 days) despite higher documented infections and febrile neutropenia for 7&3. In this multicenter real-word dataset, patients selected for intensive chemotherapy had superior OS but a large group had similar outcomes with ven/HMA. Prospective randomized studies, controlling for both measured and unmeasured confounders, must confirm this outcome.
引用
- Matthews AH, Perl AE, Luger SM, et al. Real-world effectiveness of intensive chemotherapy with 7&3 versus venetoclax and hypomethylating agent in acute myeloid leukemia. Am J Hematol. 2023. PMID: 37334852. doi:10.1002/ajh.26991
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。